Memorial Sloan Kettering Rockville Centre

Rockville Centre, New York 11570

0 studies enrolling now · 46 studies all time

What they study most

Amyloidosis, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation, Bladder Cancer, Breast Cancer, Breast Neoplasms, Chronic Pain, Colorectal Cancer, Diffuse Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), EGFR Gene Mutation, EGFR-Mutant Lung Cancer

Studies at this site

• A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors — Running, not enrolling
• Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer — Running, not enrolling
• Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer — Running, not enrolling
• Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy — Running, not enrolling
• Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer — Running, not enrolling
• Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma — Running, not enrolling
• Proton Re-Irradiation for Recurrent Head and Neck Cancer — Completed
• Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers — Running, not enrolling
• Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung — Running, not enrolling
• Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy — Running, not enrolling
• Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer — Completed
• PEACE: Comparing Chronic Pain Treatment Options — Running, not enrolling
• Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer — Completed
• Evaluating an Alternative Clinical Genetics Cancer Care Delivery Model: A Pilot Study of Patient Outcomes — Running, not enrolling
• Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer — Running, not enrolling
• A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone — Completed
• Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer — Completed
• A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib. — Completed
• Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma — Completed
• A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer — Completed
• Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer — Stopped early
• Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma — Stopped early
• PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery — Status unconfirmed
• Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery — Running, not enrolling
• Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer — Completed
• Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma — Completed
• Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation — Completed
• Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer — Completed
• Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer — Completed
• Study of Proton Radiation to the Brain and Spinal Cord for Patients With Leptomeningeal Metastases — Completed
• Adaptive Radiotherapy for Head and Neck Cancer — Completed
• Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer — Completed
• Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases — Completed
• A Single Center Randomized Controlled Trial Assessing Pain and Quality of Life Following Surgery — Completed
• Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers — Completed
• Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors — Completed
• Beyond Performance Status: Electronic Activity Monitoring to Assess Functional Activity of Patients With Gastrointestinal Malignancy During Chemotherapy. — Completed
• Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery — Stopped early
• Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis — Completed
• Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer — Completed
• Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma — Stopped early
• Electronic Reporting of Symptoms After Surgery — Completed
• A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study) — Stopped early
• Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer — Completed
• A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma — Withdrawn before enrolling
• Alisertib in Treating Patients With Advanced or Metastatic Sarcoma — Completed